Catherine Dargan

Catherine J. Dargan

Download V-card

Covington & Burling LLP
One CityCenter
850 Tenth Street, NW
Washington, DC 20001-4956
Tel: +1 202 662 5567



  • Harvard Law School, J.D., 1994
    • cum laude
  • Stanford University, A.B., 1991
    • with honors

Judicial Clerkship

  • Hon. Matthew J. Perry, U.S. District Court, District of South Carolina, 1994-1995

Bar Admissions

  • California
  • District of Columbia

Catherine Dargan is co-chair of Covington’s Mergers & Acquisitions practice and a member of the firm's Management Committee.  She has broad experience in mergers and acquisitions, both public and private, and strategic partnering arrangements.  In addition to structuring and negotiating transactions, she assists clients with corporate governance, compliance and other matters.  Ms. Dargan also regularly advises clients on a variety of commercial agreements relating to manufacturing, supply, and distribution of core products.  She represents clients in a variety of industries including life sciences, consumer products, technology, defense and government contracting, media, sports, and equipment and manufacturing.

Representative Matters

  • AstraZeneca in its:
    • $600 million acquisition of Actavis’ branded respiratory business in the US and Canada;
    • $1.26 billion acquisition of Ardea Biosciences (NASDAQ: RDEA);
    • up to $4.3 billion acquisition of Bristol-Myers Squibb's interests in the companies’ diabetes alliance in initial consideration and regulatory, launch and sales-related payments;
    • approximately $3.5 billion strategic diabetes alliance with Bristol-Myers Squibb in connection with BMS’s acquisition of Amylin Pharmaceuticals, including assistance in structuring agreements for the acquisition and operation of Amylin’s diabetes business by AZ and BMS;
    • acquisition of AlphaCore Pharma by MedImmune, AstraZeneca's biologic arm; and
    • $325 million divestiture of assets relating to Myalept.
  • Salix Pharmaceuticals in its:
    • $2.6 billion acquisition of Santarus, Inc. (NASDAQ: SNTS); and
    • $300 million acquisition of Oceana Therapeutics, Inc.
  • Aristocrat Technologies in its $1.28 billion acquisition of Video Gaming Technologies.
  • Boehringer Ingelheim in its:
    • $300 million sale of its sterile injectables generics business (Bedford Laboratories); and
    • acquisition of certain animal health products divested in connection with the Pfizer-Wyeth merger.
  • Takeda in its acquisition of Intellikine, Inc. for $190 million upfront and up to $120 million in additional potential clinical development milestone payments. 

Honors and Rankings

  • The National Law Journal, "Outstanding Women Lawyers" (2015)   
  • Named as "Best in Mergers & Acquisitions" by Euromoney Legal Media Group, Americas Women in Business Law Awards (2014)
  • Chambers USA, Corporate/M&A & Private Equity (2014-2015)
  • National Law Journal, D.C. Corporate Deal Makers (2013)
  • LMG Life Sciences, “Life Science Star” (2012-2014)
  • Legal 500 US
    • Leading Lawyer in M&A: Large deals ($1B-$5B) (2014)
    • M&A: Large deals ($1B-$5B) (2012-2015)
    • Healthcare: Life Sciences (2013-2014)
    • Media, Technology and Telecoms (2014)

Pro Bono

  • Represented a non-profit, non-partisan policy organization dedicated to engaging young adults in the political process.
  • Advised a non-profit in various consulting and services arrangements.

Memberships and Affiliations

  • Law360, Mergers & Acquisitions Editorial Advisory Board (2012-present)

Publications and Speeches

  • "Life Sciences Acquisitions and Divestitures: Special Considerations," Practising Law Institute (4/9/2015)
  • "Life Sciences Acquisitions and Divestitures," Faculty Member, Practising Law Institute (2015)
  • "Drafting Corporate Agreements — Letters of Intent, Confidentiality and Standstill Agreements," Faculty Member, Practising Law Institute (2011, 2012 and 2014)
Print PDF Word Version Print this page

Inside Medical Devices Blog